glp 1 drugs origin Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GIPR/GLP-1R dual agonist therapies for

2, the meta-analysis of all available cohorts showed a significant reduction in risk for schizophrenia (OR = 0.72, 95% CI [0.610.86]), bipolar disorder (OR = 0.91, 95% CI [0.880.94]), bulimia nervosa (OR = 0.34, 95% CI [0.230.52]), PTSD (OR = 0.45, 95% CI [0.310.67]), and autism (OR = 0.55, 95% CI [0.320.93])

More specifically, the interaction of GLP-1 and GLP-1R activates adenylate cyclase (AC), which stimulates the conversion of ATP to cyclic adenosine monophosphate (cAMP), thereby increasing the concentration of cAMP

DOI: 10.2337/db10-0474 Shaefer CF Jr et al (2015): User's guide to mechanism of action and clinical use of GLP-1 receptor agonists

NMA, network meta-analysis

Wang L., et al

Both use once-weekly subcutaneous injections